期刊文献+

高效液相色谱串联质谱电喷雾检测法快速测定人尿中帕洛诺司琼的浓度

Rapid determination of palonosetron in urine by LC-ESI-MS/MS
原文传递
导出
摘要 目的:建立快速测定人尿中帕洛诺司琼浓度的高效液相色谱串联质谱电喷雾检测法(LC-ESI-MS/MS)。方法:以AgilentTCC18柱(4.6mm×150mm,5μm)为色谱柱;流动相为乙腈-0.04mol.L-1甲酸铵水溶液(含0.04%甲酸)(69∶31),流速0.6mL·min-1;柱温25℃;醋酸乙酯-二氯甲烷(4∶1)为提取剂。样品经电喷雾离子源正离子化后,样品通过三重四级杆串联质谱仪,采用选择反应监测(SRM)对帕洛诺司琼(m/z297.2→82.2)和内标地西泮(m/z285.1→154.0)测定。结果:帕洛诺司琼高(80μg.L-1)、中(50μg.L-1)、低(5μg.L-1)3个浓度的平均回收率RSD均小于15%;线性范围为2.5~100μg.L-1,回归方程为F=27.135ρ-0.0582,r=0.9999(n=6),权重系数为1/ρ,分析方法的最低定量限为2.5μg.L-1。结论:该方法灵敏、准确、简单、快速,可用于帕洛诺司琼临床尿药浓度监测和药动学研究。 OBJECTIVE To set up a LC-ESI-MS/MS method for palonosetron assay in urine. METHODS Palonosetron was extracted with ethyl acetate dichloromethane. The residues were analyzed with a LOESI MS/MS system (Agilent TC C18 column,4. 6 mm× 150 mm, 5 μm) with the mobile phase consisted of acetonitrile with 0. 04 mmol, L^-1 ammonium formate (0. 04% formic acid ) = 69:31 (V: V). The flow rate was 0. 6 mL·min ^-1. A Agilent 6410 triple quad mass spectrometer sys tern equipped with an electrospray ionization ion trap source was used as the detector and operated in the positive ion mode. Se lected reaction monitoring(SRM) using the precursor to produce combinations of m/z 297. 2→82. 2 and m/z 285. 1→154. 0 was performed to detect palonosetron and the internal standard, respectively. RESULTS The average recoveries for palonosetron were 69.00% ,69.75% ,71.61% ,respectively. The within-day (n = 5) and between day (n = 3) precision of variation was less than 15 %. The calibration curves for palonosetron had good linearity, r = 0. 999 9(n = 6),over the range of 2.5 - 100 μg·L^-1. The limits of quantitation for palonosetron was 2. 5 μg·L^-1. CONCLUSION The method provides a sensitive,accurate, precise and reliable analytical procedure for clinical monitoring of palonosetron in urine and for its phamacokinetic studies.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2010年第14期1183-1186,共4页 Chinese Journal of Hospital Pharmacy
基金 广东省自然科学研究基金资助项目(编号:8151037001000001) 广东省医学科研基金立项(编号:A2008559) 广东省医院药学研究基金资助项目(编号:2008B001)
关键词 帕洛诺司琼 尿药浓度 高效液相色谱串联质谱电喷雾法 palonosetron urine concentration LC ESI-MS/MS
  • 相关文献

参考文献4

二级参考文献19

  • 1丁黎,杨劲,李荣珊,周梅,沈建平,张银娣.福多司坦在健康受试者体内的药代动力学[J].药学学报,2005,40(10):945-949. 被引量:10
  • 2HFSKETH P J.Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting[J].Cancer Invest,2000,18 (2):163-173.
  • 3LINDLEY C M,BERNARD S,FIELDS S M.Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population[J].J Clin Oncol,1989,7 (8):1142-1149.
  • 4GREGORY R E,ETTINGER D S.5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.A comparison of their pharmacology and clinical efficacy[J].Drugs,1998,55(2):173-189.
  • 5STOLTZ R,CYONG J,SHAH A,et al.Pharmacokinetic and safety evaluation of palonosetron,a 5-hydroxytryptamine-3 receptor antagonist,in US and Japanese healthy subjects[J].J Clin Pharmacol,2004,44(5):520-531.
  • 6STOLTZ R,PARISI S,SHAH A,et al.Pharmacokinetics,metabolism and excretion of intravenous[14C]-palonosetron in healthy human volunteers[J].Biopharm Drug Dispos,2004,25(8):329-337.
  • 7Hesketh PJ.Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting[J].Cancer Invest,2000,18:163-173.
  • 8Geling O,Eichler HG.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implications[J].J Clin Oncol,2005,23(6):1289-1294.
  • 9Gralla R,Lichinitser M,Vegt SV,et al.Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy:results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron[J].Ann of Oncol,2003,14(10):1570-1577.
  • 10Eisenberg P,Figueroa-Vadillo J,Zamora R,et al.Improved prevention of moderately emeto-genic chemotherapy-induced nausea and vomiting with palonosetron,a pharmacologically novel 5-HT3 receptor antagonist:results of a phase Ⅲ,single-dose trial versus dolasetron[J].Cancer,2003,98(11):2473-2482.

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部